Aequus Pharmaceuticals Inc. (AQS.V)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 254.89 Thousand CAD | -81.53% |
| 2022 | 1.37 Million CAD | -49.17% |
| 2021 | 2.71 Million CAD | 4.71% |
| 2020 | 2.59 Million CAD | 58.81% |
| 2019 | 1.63 Million CAD | 15.76% |
| 2018 | 1.41 Million CAD | 23.77% |
| 2017 | 1.13 Million CAD | 62.4% |
| 2016 | 701.63 Thousand CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 52.55 Thousand CAD | 3.3% |
| 2024 Q2 | 161.41 Thousand CAD | 207.13% |
| 2023 Q1 | 92.25 Thousand CAD | -75.92% |
| 2023 Q2 | 98.4 Thousand CAD | 6.68% |
| 2023 Q4 | 50.87 Thousand CAD | 280.84% |
| 2023 Q3 | 13.35 Thousand CAD | -86.43% |
| 2023 FY | 254.89 Thousand CAD | -81.53% |
| 2022 Q4 | 383.07 Thousand CAD | 10.1% |
| 2022 Q2 | 346.49 Thousand CAD | 14.63% |
| 2022 Q1 | 302.28 Thousand CAD | -64.82% |
| 2022 FY | 1.37 Million CAD | -49.17% |
| 2022 Q3 | 347.92 Thousand CAD | 0.41% |
| 2021 Q2 | 651.51 Thousand CAD | 32.47% |
| 2021 Q4 | 859.32 Thousand CAD | 20.69% |
| 2021 FY | 2.71 Million CAD | 4.71% |
| 2021 Q1 | 491.82 Thousand CAD | -42.22% |
| 2021 Q3 | 712.03 Thousand CAD | 9.29% |
| 2020 FY | 2.59 Million CAD | 58.81% |
| 2020 Q3 | 618.98 Thousand CAD | 14.0% |
| 2020 Q2 | 542.99 Thousand CAD | -6.29% |
| 2020 Q1 | 579.45 Thousand CAD | 8.21% |
| 2020 Q4 | 851.18 Thousand CAD | 37.51% |
| 2019 Q2 | 397.26 Thousand CAD | 20.75% |
| 2019 FY | 1.63 Million CAD | 15.76% |
| 2019 Q3 | 370.79 Thousand CAD | -6.66% |
| 2019 Q1 | 328.99 Thousand CAD | 38.68% |
| 2019 Q4 | 535.46 Thousand CAD | 44.41% |
| 2018 Q4 | 237.22 Thousand CAD | -43.54% |
| 2018 FY | 1.41 Million CAD | 23.77% |
| 2018 Q2 | 377.85 Thousand CAD | 0.76% |
| 2018 Q3 | 420.15 Thousand CAD | 11.2% |
| 2018 Q1 | 375 Thousand CAD | 1.71% |
| 2017 Q1 | 293 Thousand CAD | 75.55% |
| 2017 FY | 1.13 Million CAD | 62.4% |
| 2017 Q4 | 368.68 Thousand CAD | 26.63% |
| 2017 Q3 | 291.15 Thousand CAD | 56.04% |
| 2017 Q2 | 186.58 Thousand CAD | -36.32% |
| 2016 Q1 | 116.08 Thousand CAD | 0.0% |
| 2016 FY | 701.63 Thousand CAD | 0.0% |
| 2016 Q2 | 118.1 Thousand CAD | 1.74% |
| 2016 Q4 | 166.9 Thousand CAD | -44.47% |
| 2016 Q3 | 300.54 Thousand CAD | 154.49% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| CanadaBis Capital Inc. | 22.22 Million CAD | 98.853% |
| Decibel Cannabis Company Inc. | 115.95 Million CAD | 99.78% |
| Delivra Health Brands Inc. | 12.37 Million CAD | 97.941% |
| Entourage Health Corp. | 40.71 Million CAD | 99.374% |
| Lifeist Wellness Inc. | 21.65 Million CAD | 98.823% |
| Cannara Biotech Inc. | 57.26 Million CAD | 99.555% |
| Medicure Inc. | 21.69 Million CAD | 98.825% |
| PharmaCielo Ltd. | 1.54 Million CAD | 83.467% |
| Rubicon Organics Inc. | 40.11 Million CAD | 99.365% |
| BioSyent Inc. | 31.59 Million CAD | 99.193% |
| Voyageur Pharmaceuticals Ltd. | - CAD | -Infinity% |